196 related articles for article (PubMed ID: 15741769)
1. Minimizing the immunogenicity of antibodies for clinical application.
Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV
Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769
[TBL] [Abstract][Full Text] [Related]
2. SDR grafting--a new approach to antibody humanization.
Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
[TBL] [Abstract][Full Text] [Related]
3. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
[TBL] [Abstract][Full Text] [Related]
4. Humanization by CDR grafting and specificity-determining residue grafting.
Kim JH; Hong HJ
Methods Mol Biol; 2012; 907():237-45. PubMed ID: 22907355
[TBL] [Abstract][Full Text] [Related]
5. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
6. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
7. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
8. Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity.
Mateo C; Lombardero J; Moreno E; Morales A; Bombino G; Coloma J; Wims L; Morrison SL; Pérez R
Hybridoma; 2000 Dec; 19(6):463-71. PubMed ID: 11152398
[TBL] [Abstract][Full Text] [Related]
9. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
[TBL] [Abstract][Full Text] [Related]
10. A general approach to antibody thermostabilization.
McConnell AD; Zhang X; Macomber JL; Chau B; Sheffer JC; Rahmanian S; Hare E; Spasojevic V; Horlick RA; King DJ; Bowers PM
MAbs; 2014; 6(5):1274-82. PubMed ID: 25517312
[TBL] [Abstract][Full Text] [Related]
11. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
12. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
13. Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells.
Hernández T; de Acosta CM; López-Requena A; Moreno E; Alonso R; Fernández-Marrero Y; Pérez R
Mol Immunol; 2010; 48(1-3):98-108. PubMed ID: 20952071
[TBL] [Abstract][Full Text] [Related]
14. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
[TBL] [Abstract][Full Text] [Related]
15. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.
Tan P; Mitchell DA; Buss TN; Holmes MA; Anasetti C; Foote J
J Immunol; 2002 Jul; 169(2):1119-25. PubMed ID: 12097421
[TBL] [Abstract][Full Text] [Related]
16. Engineering fully human monoclonal antibodies from murine variable regions.
Bernett MJ; Karki S; Moore GL; Leung IW; Chen H; Pong E; Nguyen DH; Jacinto J; Zalevsky J; Muchhal US; Desjarlais JR; Lazar GA
J Mol Biol; 2010 Mar; 396(5):1474-90. PubMed ID: 20045416
[TBL] [Abstract][Full Text] [Related]
17. A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.
Haidar JN; Yuan QA; Zeng L; Snavely M; Luna X; Zhang H; Zhu W; Ludwig DL; Zhu Z
Proteins; 2012 Mar; 80(3):896-912. PubMed ID: 22180101
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.
Harding FA; Stickler MM; Razo J; DuBridge RB
MAbs; 2010; 2(3):256-65. PubMed ID: 20400861
[TBL] [Abstract][Full Text] [Related]
19. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
[TBL] [Abstract][Full Text] [Related]
20. Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.
Apgar JR; Mader M; Agostinelli R; Benard S; Bialek P; Johnson M; Gao Y; Krebs M; Owens J; Parris K; St Andre M; Svenson K; Morris C; Tchistiakova L
MAbs; 2016 Oct; 8(7):1302-1318. PubMed ID: 27625211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]